Horizon Therapeutics plc Receives European Commission (EC) Approval of UPLIZNA® (inebilizumab) for the Treatment of Adults with Neuromyelitis Optica Spectrum Disorder (NMOSD) - PharmiWeb.com

-- NMOSD is a devastating autoimmune disease of severe and recurrent central nervous system attacks which can result in blindness, paralysis and death ---- UPLIZNA is indicated as monotherapy for treatment of adult patients with NMOSD who are anti-aquaporin-4…

-- NMOSD is a devastating autoimmune disease of severe and recurrent central nervous system attacks which can result in blindness, paralysis and death -- -- UPLIZNA is indicated as monotherapy for t… [+14156 chars]

full article...